BACKGROUND: Allogeneic blood transfusion can result in an immune response against major histocompatibility complex (MHC) antigens, potentially complicating future transfusions or transplants. We previously demonstrated that pathogen reduction of platelet-rich plasma (PRP) with riboflavin and ultraviolet light (UV+R) can prevent alloimmunization in mice. A similar pathogen-reduction treatment is currently under development for the treatment of whole blood using riboflavin and a higher dose of UV light. We sought to determine the effectiveness of this treatment in the prevention of alloimmunization. STUDY DESIGN AND METHODS: BALB/cJ mice were transfused with untreated or UV+R-treated, allogeneic C57Bl/6J whole blood with or without leukoreduction. Mice were evaluated for donor-specific antibodies, ex vivo splenocyte cytokine responses, and changes in the frequency of regulatory T (Treg ) cells. RESULTS: UV+R treatment blocked cytokine priming and reduced anti-MHC alloantibody responses to transfused whole blood. Leukoreduction reduced alloantibody levels in both the untreated and UV+R-treated groups. Mice transfused with UV+R-treated whole blood had reduced alloantibody and cytokine responses when subsequently transfused with untreated blood from the same donor type. This reduction in responses was not associated with increased Treg cells. CONCLUSIONS: Pathogen reduction of whole blood with UV+R significantly reduces, but does not eliminate, the alloimmune response. Exposure to UV+R-treated whole blood transfusion does appear to induce tolerance to alloantigens, resulting in reduced anti-MHC alloantibody and cytokine responses to subsequent exposures to the same alloantigens. This tolerance does not appear to be driven by an increase in Treg cells.
BACKGROUND: Allogeneic blood transfusion can result in an immune response against major histocompatibility complex (MHC) antigens, potentially complicating future transfusions or transplants. We previously demonstrated that pathogen reduction of platelet-rich plasma (PRP) with riboflavin and ultraviolet light (UV+R) can prevent alloimmunization in mice. A similar pathogen-reduction treatment is currently under development for the treatment of whole blood using riboflavin and a higher dose of UV light. We sought to determine the effectiveness of this treatment in the prevention of alloimmunization. STUDY DESIGN AND METHODS: BALB/cJ mice were transfused with untreated or UV+R-treated, allogeneic C57Bl/6J whole blood with or without leukoreduction. Mice were evaluated for donor-specific antibodies, ex vivo splenocyte cytokine responses, and changes in the frequency of regulatory T (Treg ) cells. RESULTS: UV+R treatment blocked cytokine priming and reduced anti-MHC alloantibody responses to transfused whole blood. Leukoreduction reduced alloantibody levels in both the untreated and UV+R-treated groups. Mice transfused with UV+R-treated whole blood had reduced alloantibody and cytokine responses when subsequently transfused with untreated blood from the same donor type. This reduction in responses was not associated with increased Treg cells. CONCLUSIONS: Pathogen reduction of whole blood with UV+R significantly reduces, but does not eliminate, the alloimmune response. Exposure to UV+R-treated whole blood transfusion does appear to induce tolerance to alloantigens, resulting in reduced anti-MHC alloantibody and cytokine responses to subsequent exposures to the same alloantigens. This tolerance does not appear to be driven by an increase in Treg cells.
Authors: M G Massad; D J Cook; S K Schmitt; N G Smedira; J F McCarthy; R L Vargo; P M McCarthy Journal: Ann Thorac Surg Date: 1997-10 Impact factor: 4.330
Authors: G Andreu; J Dewailly; C Leberre; M C Quarre; M L Bidet; R Tardivel; L Devers; Y Lam; E Soreau; C Boccaccio Journal: Blood Date: 1988-09 Impact factor: 22.113
Authors: K Sintnicolaas; M van Marwijk Kooij; H C van Prooijen; B A van Dijk; W L van Putten; F H Claas; V M Novotny; A Brand Journal: Blood Date: 1995-02-01 Impact factor: 22.113
Authors: Jean-Pierre Allain; Alex K Owusu-Ofori; Sonny Michael Assennato; Susanne Marschner; Raymond P Goodrich; Shirley Owusu-Ofori Journal: Lancet Date: 2016-04-23 Impact factor: 79.321
Authors: Andrew P Cap; Heather F Pidcoke; Shawn D Keil; Hilary M Staples; Manu Anantpadma; Ricardo Carrion; Robert A Davey; Ashley Frazer-Abel; Audra L Taylor; Richard Gonzales; Jean L Patterson; Raymond P Goodrich Journal: Transfusion Date: 2016-03 Impact factor: 3.157
Authors: Veronika Brixner; Gesine Bug; Petra Pohler; Doris Krämer; Bernd Metzner; Andreas Voss; Jochen Casper; Ulrich Ritter; Stefan Klein; Nael Alakel; Rudolf Peceny; Hans G Derigs; Frank Stegelmann; Martin Wolf; Hubert Schrezenmeier; Thomas Thiele; Erhard Seifried; Hans-Hermann Kapels; Andrea Döscher; Eduard K Petershofen; Thomas H Müller; Axel Seltsam Journal: Haematologica Date: 2021-04-01 Impact factor: 9.941